Projects
While many of the projects Metaphase works on are confidential, below are a few examples of our work. A more comprehensive list of projects and work samples are available upon request.
Externally-Led Patient-Focused
Drug Development (EL-PFDD) Meeting for ARPKD Patients and their Families
Dry Age-Related Macular Degeneration (AMD) Externally-Led Patient Focused Drug Development Meeting (EL-PFDD)
AI in Clinical Medicine: A practical Guide for Healthcare Professionals. Published in March 2023
Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia (ARVC/D) Voice of the Patient report
Wiskott Aldrich Syndrome (WAS) and X-Linked Thrombocytopenia (XLT) Voice of the Patient Report
Kennedy’s Disease (KD)/ Spinal and bulbar muscular atrophy (SBMA) Voice of the Patient Report
The Endocannabinoid System (ECS) A Physician’s Guide. Produced in collaboration with Shannon Chiarenza, graphic design
Your Endocannabinoid System Explained (ECS) Consumer guide. Produced in collaboration with Shannon Chiarenza, graphic design.
Voice of the Patient Report: HLAA’s Externally-Led Patient-Focused Drug Development (PFDD) Meeting for People and Families Living with Sensorineural Hearing Loss
THE VOICE OF THE PATIENT: Living with polyglutamine Spinocerebellar Ataxias (SCA) and Dentatorubal-Pallidoluysian Atrophy (DRPLA), an Externally-Led PFDD Meeting Report
Quality of life in a real-world study of patients with metastatic colorectal cancer treated with trifluridine/tipiracil
Real-world use of trifluridine/tipiracil for patients with metastatic colorectal
cancer in Canada.
Reducing time from colon cancer surgery to initiation of adjuvant chemotherapy:
pilot project.
A catalyst for transforming health systems and person-centred care: Canadian national position statement on patient-reported outcomes.
Canadian consensus: oligoprogressive, pseudoprogressive, and oligometastatic non-small-cell lung cancer.
A phase II trial of the effect of perindopril on hand–foot skin reaction (HFSR) incidence and severity in patients receiving regorafenib for refractory mCRC.
An Evolving Algorithm to Select and Sequence Therapies in EGFR Mutation-positive NSCLC: A Strategic Approach.
Canadian consensus: inhibition of ALK-positive tumours in advanced non-small-cell lung cancer.
